Loading...
Patients with advanced symptomatic heart failure are at considerable risk for premature death, hospitalization, and functional limitation, even when receiving the most current evidence-based therapy. Nesiritide, a recombinant B-type natriuretic peptide, holds theoretical appeal as an adjunct to standard therapy because of its vasodilatory and natriuretic effects. It is approved for acute treatment of decompensated heart failure; however, it has also been commonly administered via intermittent outpatient infusion, despite a lack of data to support this practice. The Follow-Up Serial Infusions of Nesiritide (FUSION I) trial found no benefit from intermittent nesiritide infusions in outpatients with heart failure, but the findings suggested th…